Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Denileukin Diftitox (Ontak) Clear all
Terminated Phase 1 Interventional Results available

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

NCT01251952
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Denileukin Diftitox (Ontak)
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma

NCT00006345
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Interventions
denileukin diftitox, dexamethasone
Biological · Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
11
States / cities
Miami, Florida • Chicago, Illinois • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

NCT00211276
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
ONTAK (denileukin diftitox)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)

NCT00493129
View directory record Official record
Conditions
Leukemia, Systemic Mastocytosis
Interventions
Ontak (Denileukin Diftitox)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Oct 1, 2026, 1:59 AM EDT
Withdrawn Phase 2 Interventional

Denileukine Diftitox for Relapsed ALCL

NCT00801918
View directory record Official record
Conditions
Anaplastic Large-Cell Lymphoma
Interventions
Denileukin Diftitox, Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
Drug
Lead sponsor
Columbia University
Other
Eligibility
2 Years to 24 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 1, 2026, 1:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

NCT05200559
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Pembrolizumab, E7777
Drug
Lead sponsor
Alexander B Olawaiye, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer

NCT00082914
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
denileukin diftitox
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 1, 2026, 1:59 AM EDT
Withdrawn Not applicable Interventional

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

NCT00513188
View directory record Official record
Conditions
Lymphoma
Interventions
denileukin diftitox, cyclophosphamide, cytarabine, doxorubicin hydrochloride, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, protein expression analysis, flow cytometry, laboratory biomarker analysis
Biological · Drug · Genetic + 1 more
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 1, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

NCT00632827
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection, Granulocyte-colony stimulating factor (G-CSF), Pegfilgrastim, Cyclophosphamide, Vincristine, Leucovorin, Methotrexate, Doxorubicin Hydrochloride, Cytarabine, Etoposide, Carmustine, Denileukin diftitox
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 1, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

NCT00117845
View directory record Official record
Conditions
Leukemia, Adult T-Cell
Interventions
Denileukin diftitox (Ontak)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Combination Daclizumab/Denileukin Diftitox to Treat Uveitis

NCT00326508
View directory record Official record
Conditions
Non-infectious Intermediate and Posterior Uveitis
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 4 Interventional

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

NCT00050999
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome
Interventions
ONTAK
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2008 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

NCT00357448
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
denileukin diftitox, intraperitoneal administration, laboratory biomarker analysis, enzyme-linked immunosorbent assay, flow cytometry
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

NCT00211185
View directory record Official record
Conditions
Lymphoma, T-Cell, Peripheral
Interventions
Denileukin diftitox, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Pegfilgrastim
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00128622
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

NCT00055146
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic
Interventions
ONTAK
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
5
States / cities
Fountain Valley, California • La Jolla, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2009 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma

NCT00337987
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Ontak, CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

NCT01127451
View directory record Official record
Conditions
Stage IIIC Melanoma, Stage IV Melanoma
Interventions
Denileukin diftitox
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

NCT00003615
View directory record Official record
Conditions
Lymphoma
Interventions
denileukin diftitox
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

NCT00425672
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
ONTAK, flow cytometry, immunohistochemistry staining method, enzyme-linked immunosorbent assay, laboratory biomarker analysis, protein expression analysis
Biological · Other · Genetic
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia

NCT00082940
View directory record Official record
Conditions
Leukemia
Interventions
denileukin diftitox
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
11
States / cities
Orange, California • Chicago, Illinois • Vincennes, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

NCT01181258
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Rituximab, Interleukin-2, Natural killer cells, Cyclophosphamide, Methylprednisolone, Fludarabine
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 1, 2026, 1:59 AM EDT
Not listed Phase 2 Interventional

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

NCT00026429
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
denileukin diftitox
Biological
Lead sponsor
Pharmatech Oncology
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
6
States / cities
Pomona, California • Rancho Mirage, California • Saint Charles, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 1, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

NCT00082758
View directory record Official record
Conditions
Neuroblastoma
Interventions
hu14.18-Interleukin-2 fusion protein
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
69
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 1, 2026, 1:59 AM EDT